Mission Bio’s Tapestri Platform Leveraged by Top Academic and Pharma Institutions to Pinpoint Disease-Driving Clones in Multiple Myeloma

Recent data suggests the potential of single-cell DNA and cell surface proteogenomics for detection and surveillance of multiple myeloma and other heme malignancies, pioneering a path to precision therapeutics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, the pioneer in high-throughput, targeted single-cell DNA and multi-omics analysis, announced data underscoring the ability of the Tapestri® Platform to potentially impact cancer therapy by correlating cell surface protein expression of potential therapeutic targets with multiple myeloma (MM) clonal populations. This breakthrough data demonstrates the potential for single-cell multi-omics to improve myeloma patient stratification and disease surveillance.

Annually, MM, a blood cancer originating from bone marrow, results in approximately 200,000 new diagnoses globally. Despite advancements in blood cancer research, MM showcases a daunting 100% relapse rate and a mere 54% five-year survival rate, prompting a wave of precision therapy development. Mission Bio's Tapestri Platform is a unique tool that provides detailed information on clonal evolution and potential therapeutic targets at a single-cell level of resolution. Such insights into MM, acute myeloid leukemia (AML), and other blood cancers could augment, or even replace, multiple other assays that each provide only a fraction of the patient’s disease characteristics.

At two recent industry-leading events, Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio, and Adam Sciambi, PhD, co-founder and Chief Technology Officer at Mission Bio, took center stage to present this late-breaking MM data generated by Hervé Avet-Loiseau, MD, PhD, from The Cancer Research Center of Toulouse, and Genentech’s Director of Translational Medicine, Cedric Dos Santos, PhD. In the novel, proof-of-concept project, the Tapestri Platform was used to characterize the clonal architecture of multiple MM patient samples by single nucleotide variants (SNVs), copy number variants (CNVs), and surface immunophenotypes — marrying flow cytometry and bulk next-generation sequencing (NGS), but offering single-cell resolution.

The approach demonstrates the potential of Tapestri to move beyond a binary “yes/no” answer to the presence or absence of disease, but also provide researchers and clinicians with critical information about MM disease progression and offer actionable personalized therapeutic target information that could enhance patient outcomes. The data were presented at the 13th World Clinical Biomarkers & CDx Summit and the 20th International Myeloma Society Annual Meeting and Exposition.

“Following our successful launch of the scMRD AML Multiomics Assay, where clinician researchers from Memorial Sloan Kettering Cancer Center and Erasmus MC utilized the Tapestri to characterize relapse and recurrence in AML, we are excited now to see institutions like The Cancer Research Center of Toulouse and Genentech demonstrate additional Tapestri capabilities in MM clonal profiling and surveillance,” said Dr. Druley. “At Mission Bio, we are dedicated to supporting our academic and pharma customers by providing novel solutions to advance research and the deployment of personalized therapy for these debilitating blood cancers.”

Mission Bio will host a webinar titled “Myeloma Matters: Advancing Research and Therapy Development with Single-cell DNA + Protein Multi-Omics” on October 18, 2023, with Dr. Druley and Dr. Sciambi. Registration is open to the public and additional information can be found here.

About Mission Bio

Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.

Media Contact
Consort Partners for Mission Bio
missionbio@consortpartners.com